(Q24244963)

English

Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

0 references

1 reference

Europe PubMed Central

Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles (English)

0 references

desensitization

1 reference

based on heuristic

inferred from title

Humberto Saconato

2

0 references

author name string

Luiz Eduardo Trevisan Albuquerque

1

0 references

Maria Cecília Romano Maciel

3

0 references

L O Tso

4

0 references

publication date

24 January 2005

0 references

Cochrane Database of Systematic Reviews

0 references

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro-results of a prospective, randomized in-vitro fertilization study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Combination of long and short term GnRH analogue protocols: a new therapeutic approach to persistent high progesterone levels in IVF cycles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Long-term down-regulation does not improve pregnancy rates in an in vitro fertilization program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Effects of gonadotrophin-releasing hormone agonists (GnRHa) on follicle and oocyte quality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Efficacy of nafarelin in assisted reproductive technology: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

21 January 2018

Clinical aspects with regard to the occurrence of an endogenous luteinizing hormone surge in gonadotropin-induced normal menstrual cycles

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (Buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Should gonadotropin-releasing hormone down-regulation therapy be routine in in vitro fertilization?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of gonadotropin-releasing hormone analogs for in vitro fertilization: comparison between the standard form and long-acting formulation of D-Trp-6-luteinizing hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

[Comparison of a long-acting and short-acting GnRH analog in combination with gonadotropins in in vitro fertilization under various indications]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined GnRH-agonist/gonadotrophin stimulation for in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrinology: Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: a comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pituitary down-regulation with goserelin (Zoladex) for in vitro fertilisation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002808.PUB2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD002808.PUB2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24244963&oldid=1501792940"